Dendritic Cells and Antiphospholipid Syndrome: An Updated Systematic Review

Tang, Kuo‐Tung; Chen, Hsin‐Hua; Chen, Tzu-Ting; Bracci, Nicole; Lin, Chi-Chen

doi:10.3390/life11080801

Cited by 7 publications

(1 citation statement)

References 78 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Additionally, Tang KT et al described the presence of DCs and pDCs in atheroma lesions, especially in areas of rupture, as well as a reduced number of circulating pDCs in patients with coronary heart disease, suggesting that DCs and pDCs are recruited to atherosclerotic lesion areas, decreasing their plasma levels. 24 The presence of DCs in veins affected by thrombophlebitis has also been shown, suggesting that DCs cause local inflammation not only in atherosclerosis but also in venous thrombosis. 25 Therefore, the decreased amount of circulating pDCs in t-SAPS may be explained by the recruitment of these cells to the tissues affected by the underlying autoimmune diseases, particularly SLE.…”

Section: Discussionmentioning

confidence: 98%

Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome

Santos

Vaz

Hounkpe

et al. 2022

Lupus

View full text Add to dashboard Cite

Background: Thrombotic risk in antiphospholipid syndrome (APS) is conferred by the association of antiphospholipid (aPL) antibodies (first hit) with additional pro-coagulant stimulus (second hit), such as inflammation. Among inflammatory responses, the production of large amounts of interferon (IFN)-I by plasmacytoid dendritic cells (pDCs) is at the basis of the pathophysiology of systemic autoimmune disorders, which raises the hypothesis that this mechanism could also be associated with vascular manifestations of APS. Purpose: Here, we determined the association of pDCs and IFN-I production with thrombotic APS. Research design: Patients with thrombotic primary (t-PAPS) and secondary APS (t-SAPS), asymptomatic aPL carriers and individuals without thrombosis (controls) were included. Data collection and analysis: Circulating pDCs and IFN-α intracellular expression (in the presence or not of oligodeoxynucleotides (CP) stimulus) were quantified by flow cytometry. The expression of five IFN-I inducing genes: ISG15, OASL, Ly6E, MX1, and OAS1 in mononuclear cells was determined by qPCR. Between-group differences were evaluated using chi-square or Kruskal–Wallis tests. Results: A total of 50 patients with t-PAPS, 50 patients with t-SAPS, 20 aPL carriers, and 50 individuals without thrombosis (controls) were included. Intracellular expression of IFN-α was increased after CPG stimulation in both t-SAPS (1.56%; IQR 1.07–2.02) and t-PAPS (0.96%; IQR 0.55–1.24), when compared to aPL carriers (0.71%; IQR 0.42–0.93) and controls (0.48%; IQR 0.24–0.78; p < .0001). ISG15, OASL, Ly6E, MX1, and OAS1 mRNA expressions were higher in t-SAPS (but not in t-PAPS) than in aPL carriers and controls. The expression of proteins and mRNA related to IFN-I response was similar between the triple aPL-positive profile and other aPL profiles. Conclusion: Our results indicate an association of IFN-I response and t-APS. Since IFN-I expression was not increased in aPL carriers or associated with a higher-risk aPL profile, this mechanism does not appear to be related to the presence of aPL alone. IFN-I response could possibly constitute a complementary mechanism for triggering clinical manifestations in APS.

show abstract

Section: Discussionmentioning

confidence: 98%

Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome

Santos

Vaz

Hounkpe

et al. 2022

Lupus

View full text Add to dashboard Cite

show abstract

Autoimmunity

Alkhatib

2022

The Role of Microbes in Autoimmune Diseases

View full text Add to dashboard Cite

Synergist for antitumor therapy: Astragalus polysaccharides acting on immune microenvironment

Xu,

Cheng,

Wei

et al. 2023

Discov Onc

View full text Add to dashboard Cite

Various new treatments are emerging constantly in anti-tumor therapies, including chemotherapy, immunotherapy, and targeted therapy. However, the efficacy is still not satisfactory. Astragalus polysaccharide is an important bioactive component derived from the dry root of Radix astragali. Studies found that astragalus polysaccharides have gained great significance in increasing the sensitivity of anti-tumor treatment, reducing the side effects of anti-tumor treatment, reversing the drug resistance of anti-tumor drugs, etc. In this review, we focused on the role of astragalus polysaccharides in tumor immune microenvironment. We reviewed the immunomodulatory effect of astragalus polysaccharides on macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes. We found that astragalus polysaccharides can promote the activities of macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes and induce the expression of a variety of cytokines and chemokines. Furthermore, we summarized the clinical applications of astragalus polysaccharides in patients with digestive tract tumors. We summarized the effective mechanism of astragalus polysaccharides on digestive tract tumors, including apoptosis induction, proliferation inhibition, immunoactivity regulation, enhancement of the anticancer effect and chemosensitivity. Therefore, in view of the multiple functions of astragalus polysaccharides in tumor immune microenvironment and its clinical efficacy, the combination of astragalus polysaccharides with antitumor therapy such as immunotherapy may provide new sparks to the bottleneck of current treatment methods.

show abstract

Dendritic Cells and Antiphospholipid Syndrome: An Updated Systematic Review

Cited by 7 publications

References 78 publications

Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome

Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome

Autoimmunity

Synergist for antitumor therapy: Astragalus polysaccharides acting on immune microenvironment

Contact Info

Product

Resources

About